Open Orphan PLC New Corporate Presentation

TIDMORPH

Open Orphan PLC

03 February 2020

RNS REACH

Open Orphan plc

("Open Orphan", the "Company" or the "Group")

New Corporate Presentation

Open Orphan plc (ORPH), the rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce the latest copy of its investor presentation is now available to view on https://www.openorphan.com/investors/reasons-invest.

Open Orphan was also covered this weekend in the Sunday Times due to our unique reputation as being the world leader in this space having provided services for over 30 years to the vaccine production companies around the world.

https://www.thetimes.co.uk/article/irish-firm-open-orphan-lined-up-for-role-in-coronavirus-fight-kgrnkp3f5

For further information please contact

 
 
 Open Orphan plc                                      +353 (0)1 644 0007 
  Cathal Friel, Executive Chairman                    +44 (0)20 7347 
  Trevor Phillips, Chief Executive Officer            5350 
 
 Arden Partners plc (Nominated Adviser and 
  Joint Broker)                                     +44 (0)20 7614 
  John Llewellyn-Lloyd / Benjamin Cryer              5900 
 
 Davy (Euronext Growth Adviser and Joint Broker) 
  Anthony Farrell                                   +353 (0)1 679 6363 
 
 Camarco (Financial PR) 
                                                    +44 (0)20 3757 
 Tom Huddart / Daniel Sherwen                        4980

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUOURRRBUURAR

(END) Dow Jones Newswires

February 03, 2020 05:30 ET (10:30 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024